Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials
SYDNEY, AU, May 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials ('The Summit').
The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include: - Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech - Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
Register here: https://www.eventbrite.com/e/pre-asco-china-2-gono-go-decisions-based-on-early-phase-oncology-trials-tickets-330427145487
Event Date: - China Time: 9:00-10:30 AM, Saturday, May 14, 2022 - US EST Time: 9:00-10:30 PM, Friday, May 13, 2022 - US PST Time: 6:00-7:30 PM, Friday, May 13, 2022 Language: English, with Chinese simultaneous translation Venue: Live Zoom Webinar Moderator: - Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)
The Summit will start with a presentation by Novotech's Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.
A panel discussion will follow featuring leading clinical specialists including: - Dr. Jin Li, Shanghai East Hospital - Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA - Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech - Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China - Dr. Xiaoxia Yan, Highthink - Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen - Dr. Joseph Eid, Chief Medical Officer, Hengrui - Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMS
Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.
Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.
NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.
Novotech CEO Dr. John Moller said:
"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."
"Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said.
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.
Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.
Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.
About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact
Media Contact David James communications@novotech-cro.com AU: +61 2 8218 2144 USA: +1 415 951 3228 Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro May 16, 2025 17:21 JST
|  Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America May 16, 2025 16:35 JST
|  Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States May 16, 2025 15:43 JST
|  MHI Thermal Systems Receives JSRAE Technology Award May 15, 2025 20:08 JST
|  Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology May 15, 2025 13:37 JST
|  Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets May 15, 2025 11:00 JST
|  MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station May 14, 2025 16:50 JST
|  Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects May 14, 2025 11:00 JST
|  Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security May 13, 2025 11:00 JST
|  TOYOTA GAZOO Racing fights back for double points finish May 12, 2025 15:45 JST
|  JCB and Arab Bank launch JCB merchant acquiring operations across Jordan May 12, 2025 11:00 JST
|  Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance May 09, 2025 18:57 JST
|  Valuufy Selected by Global Tech Leader for Environmental Impact Assessment May 09, 2025 18:00 JST
|  Mazda Adopts North American Charging Standard for BEVs launched in Japan May 09, 2025 16:03 JST
|  Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026 May 08, 2025 11:25 JST
|  Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV May 08, 2025 11:08 JST
|  Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China May 07, 2025 19:06 JST
|  Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition May 03, 2025 03:00 JST
|  TOYOTA GAZOO Racing Set for Spa spectacle May 02, 2025 19:29 JST
|  FWD Group reports exceptionally strong first quarter new business update May 02, 2025 17:00 JST
|
More Latest Release >>
|